Poolbeg Pharma PLC
POLB
Company Profile
Business description
Poolbeg Pharma PLC is a clinical-stage infectious disease pharmaceutical company, with a novel capital-light clinical model which enables to development of multiple products faster and more cost-effectively than the traditional biotech model. The company aspires to become a one-stop shop for pharma-seeking mid-stage products to license or acquire.
Contact
42 New Road
Queen Mary BioEnterprises Innovation Centre
LondonE1 2AX
GBRT: +44 2071831499
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
10
Stocks News & Analysis
stocks
Chart of the Week: Opportunities with wide-moat retailers
Consumer defensive names look undervalued.
stocks
New ASX share added to our best ideas
Earnings outlook is strong and the shares trade at a discount to our fair value.
stocks
Fair value downgraded for ASX heavyweight
Our capital allocation rating was also lowered due to balance sheet weakness.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,233.00 | 35.30 | 0.38% |
| CAC 40 | 7,966.95 | 71.01 | 0.90% |
| DAX 40 | 24,113.62 | 232.90 | 0.98% |
| Dow JONES (US) | 46,441.10 | 43.21 | 0.09% |
| FTSE 100 | 9,446.43 | 96.00 | 1.03% |
| HKSE | 27,180.93 | 325.37 | 1.21% |
| NASDAQ | 22,755.16 | 95.15 | 0.42% |
| Nikkei 225 | 44,794.81 | 243.96 | 0.55% |
| NZX 50 Index | 13,462.23 | 28.24 | 0.21% |
| S&P 500 | 6,711.20 | 22.74 | 0.34% |
| S&P/ASX 200 | 8,940.20 | 34.40 | 0.39% |
| SSE Composite Index | 3,882.78 | 20.25 | 0.52% |